Learn what Signatera's new EU regulatory milestone means for MRD testing, personalized cancer care, and why it matters to the testicular cancer community.
Read More
UC San Diego Health has become the first health system in the United States to clinically offer a microRNA-371a-3p blood test for testicular cancer. Developed after more than a decade of research, the test improves diagnosis, treatment planning, and surveillance, while major cancer centers nationwide continue advancing similar biomarker-based testing.
Read More